For the Inventor, By the Inventor

Enter assignee name

Fort Worth, TX, United States of America

Nacuity Pharmaceuticals, Inc.

USPTO Granted Patents = 11

CIPO Patents = 1

EPO Patents = 2

Trademarks = 2

Forward Citations = 24

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

G Michael Wall (8 out of 15 patents)

Anja Rubenstein (3 out of 4 patents)

Rodney Tucker (3 out of 4 patents)

4. Josh Bolger (3 out of 4 patents)

5. Doug Johnson (2 out of 3 patents)

6. Sambaiah Thota (2 out of 3 patents)

7. John W Lee (2 out of 3 patents)

8. Srinavasa Cheruku (2 out of 2 patents)

9. John Charles Warner (2 out of 49 patents)

10. Douglas Giles Johnson (1 out of 6 patents)

11. Peter Anthony Campochiaro (1 out of 26 patents)

12. Marcin Jakub Kowalczyk (1 out of 1 patent)

13. Craig Sheehan (1 out of 1 patent)

14. Daniel Hartman (1 out of 1 patent)

15. Jami Kern (1 out of 1 patent)

11 patents: Sort by Forward Citations

1. 12667548 - Treatment of retinitis pigmentosa and retinitis pigmentosa associated with Usher Syndrome with N-acetylcysteine amide (2026-06-30),

2. 12662449 - Method for preparation of N-acetyl cysteine amide and derivatives thereof (2026-06-23),

3. 12472157 - Treatment of retinitis pigmentosa with n-acetylcysteine amide (2025-11-18),

4. 12458608 - N-Acetylcysteine Amide (NACA) and (2R,2R')-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement (2025-11-04),

5. 12245998 - N-acetylcysteine amide (NACA) and (2R,2R')-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis (2025-03-11),

6. 11766413 - Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R')-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA) (2023-09-26),

7. 11753370 - Methods of making deuterium-enriched N-acetylcysteine amide (d-NACA) and (2R, 2R')-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA) and using d-NACA and diNACA to treat diseases involving oxidative stress (2023-09-12),

8. 11548851 - Method for preparation of n-acetyl cysteine amide and derivatives thereof (2023-01-10),

9. 10590073 - Method for preparation of N-acetyl cysteine amide and derivatives thereof (2020-03-17),

10. 9889103 - Method for the preparation of N-acetyl cysteine amide (2018-02-13),

11. 9763902 - Method for preparation of N-acetyl cysteine amide (2017-09-19),

Nacuity Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapies for ophthalmic diseases. Our mission is to improve the lives of patients suffering from serious eye conditions through cutting-edge research and development. With a commitment to scientific excellence and patient well-being, we strive to bring new and effective treatments to market to address unmet medical needs in the field of ophthalmology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

11 Patents

#78 in Fort Worth, TX

#1,720 in Texas

#27,470 in US

#51,671 in the World

Fort Worth, TX, United States of America

Nacuity Pharmaceuticals, Inc.

Forward Citations = 24

15 inventors:

G Michael Wall (8 out of 15 patents)

Anja Rubenstein (3 out of 4 patents)

Rodney Tucker (3 out of 4 patents)

4. Josh Bolger (3 out of 4 patents)

5. Doug Johnson (2 out of 3 patents)

Please report any incorrect information to [email protected]

Loading…